# Belimumab in Patients With Systemic Lupus Erythematosus

> **NCT04671706** · — · NOT_YET_RECRUITING · sponsor: **Grupo de Trabajo de Enfermedades Autoinmunes Sistémicas (GEAS) de la Fundación Española de Medicina** · enrollment: 3000 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04671706
- **Lead sponsor:** Grupo de Trabajo de Enfermedades Autoinmunes Sistémicas (GEAS) de la Fundación Española de Medicina
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2021-01
- **Primary completion:** 2025-12
- **Final completion:** 2026-12
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04671706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04671706, "Belimumab in Patients With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04671706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*